Pharsight

Oforta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7547776 SANOFI AVENTIS US Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5%
Dec, 2018

(5 years ago)

US7148207 SANOFI AVENTIS US Oral fludara of high-purity formulation with quick release of active ingredient
Dec, 2022

(1 year, 5 months ago)

Oforta is owned by Sanofi Aventis Us.

Oforta contains Fludarabine Phosphate.

Oforta has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Oforta are:

  • US7547776
  • US7148207

Oforta was authorised for market use on 18 December, 2008.

Oforta is available in tablet;oral dosage forms.

Oforta can be used as treatment of patients with b-cell chronic lymphocytic leukemia (cll).

The generics of Oforta are possible to be released after 20 December, 2022.

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Dec 18, 2011
Orphan Drug Exclusivity(ODE) Dec 18, 2015

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using FLUDARABINE PHOSPHATE ingredient

Market Authorisation Date:

18 December, 2008

Treatment:

Treatment of patients with b-cell chronic lymphocytic leukemia (cll)

Dosage:

TABLET;ORAL

More Information on Dosage

OFORTA family patents

Family Patents